| 多西紫杉醇联合卡铂治疗Ⅲb和Ⅳ期非小细胞肺癌的临床观察 |
| |
| 引用本文： | 何忠杰,庄永志,冯英,李振清,黄树峰,鲁庆峰,苑仁冰.多西紫杉醇联合卡铂治疗Ⅲb和Ⅳ期非小细胞肺癌的临床观察[J].黑龙江医药,2010,23(2):257-258. |
| |
| 作者姓名： | 何忠杰 庄永志 冯英 李振清 黄树峰 鲁庆峰 苑仁冰 |
| |
| 作者单位： | 黑龙江省大庆油田总医院肿瘤治疗中心,163001 |
| |
| 摘 要： | 目的：观察多西紫杉醇联合卡铂治疗晚期非小细胞肺癌患者的临床疗效及毒副作用。方法：经病理或细胞学证实的IIIb期和Ⅳ期非小细胞肺癌患者37例，多西紫杉醇75mg／耐，加入生理盐水中静滴1h，第1天；卡铂AUC6，第2天静滴。结果：37例患者中完全缓解（CR）2例，部分缓解（PR）18例，稳定（SD）11例，进展（PD）6例，总有效率（CR＋PR）54％，1年生存率56．7％，主要的毒副作用为骨髓抑制，大多数患者能够耐受。结论：多西紫杉醇联合卡铂治疗晚期非小细胞肺癌患者疗效确切，患者耐受良好，值得推广。
|
| 关 键 词： | 多西紫杉醇 卡铂 肺癌 |
Docetaxel and Carboplatin in Treatment of Advanced NSCLC |
| |
| Affiliation: | He Zhongjie, et al (Center for Cancer Therapy, General Hospitalof Daqing Offfield Daqing 163001 ) |
| |
| Abstract: | Objective：To observe the side effect and effect in Patients of advanced NSCLC receiving chemotherapy with doeetaxel and carboplatin. Methods： 37 patients with advanced NSCLC were verified by cytology or pathology. Docetaxel 75mg/ m2 D1 iv drip,carboplatin AUC6 D2 iv drip. Results：The cases of CR,PR and SD in 37 patients were 2,18 and 11. The general response rate was 54%. The survival rate of 1 year was 56.7%. The main side effect was bone marrow depression. Almost all patients could tolerate the side effect. Conclusion： The effect of chemotherapy with docetaxel and carboplatin to the patient of advanced NSCLC was certain, patients could tolerate the therapy, this regime was worthwhile to be extended. |
| |
| Keywords: | doeetaxel earboplatin lung cancer |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
